Marshall Wace, LLP Context Therapeutics Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 203,286 shares of CNTX stock, worth $164,661. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203,286Holding current value
$164,661% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CNTX
# of Institutions
55Shares Held
72.9MCall Options Held
0Put Options Held
0-
Bio Impact Capital LLC Cambridge, MA14.7MShares$11.9 Million2.18% of portfolio
-
Avidity Partners Management LP Dallas, TX7.48MShares$6.06 Million0.84% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$6.01 Million0.32% of portfolio
-
Nextech Invest Ag7.42MShares$6.01 Million1.37% of portfolio
-
Blue Owl Capital Holdings LP New York, NY6.36MShares$5.15 Million2.69% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $12.9M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...